Magaldrate

Identification

Name
Magaldrate
Accession Number
DB08938
Description

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 1115.3
Monoisotopic: 1111.7570627
Chemical Formula
Al5H33Mg10O40S2
Synonyms
  • Aluminium magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulphate hydrate
  • Hydrate magnesium aluminate activated sulfate
  • Magaldrate
  • Magaldrato
  • Magaldratum
  • Magnesium aluminate hydrate
  • Monalium hydrate
External IDs
  • AY 5710
  • AY-5710

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces.

Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces.

Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetaminophenMagaldrate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetophenazineMagaldrate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate.
AlfacalcidolThe serum concentration of Magaldrate can be increased when it is combined with Alfacalcidol.
AlimemazineMagaldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolThe therapeutic efficacy of Allopurinol can be decreased when used in combination with Magaldrate.
AmiodaroneThe risk or severity of hypotension can be increased when Amiodarone is combined with Magaldrate.
AmlodipineThe risk or severity of hypotension can be increased when Amlodipine is combined with Magaldrate.
AmphetamineThe serum concentration of Amphetamine can be increased when it is combined with Magaldrate.
AmprenavirMagaldrate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.

Products

International/Other Brands
Almadrat T (Actavis) / Almagel T (Balkanpharma) / Antashin (Standard) / Bemolan (Nycomed) / Cremag (Zuoz) / Glysan (Riemser) / Lowsium (Rugby) / Magacid (Purzer) / Malugastrin (Polfa Lódz) / Riopan (Nycomed) / Sanaflat (Perumed)
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Riopan Chewable Tablets 480mgTabletOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada flag
Riopan Sus 480mg/5mlSuspensionOralWhitehall Robins Inc.1993-12-312002-07-19Canada flag
Riopan Suspension 480mg/5mlSuspensionOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada flag
Riopan Tab 480mgTabletOralWhitehall Robins Inc.1993-12-312002-07-19Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Riopan Plus SusMagaldrate (480 mg) + Dimethicone (20 mg)SuspensionOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada flag
Riopan Plus SuspensionMagaldrate (96 mg) + Dimethicone (4 mg)SuspensionOralWhitehall Robins Inc.1993-12-312001-07-26Canada flag
Riopan Plus TabletsMagaldrate (480 mg) + Dimethicone (20 mg)TabletOralWhitehall Robins Inc.1993-12-311998-07-29Canada flag
Zantanol Tab.Magaldrate (100 mg/1) + Magnesium oxide (50 mg/1)TabletOralCho-A Pharm.Co.,Ltd.2020-01-31Not applicableUS flag
Zantanol Tab.Magaldrate (50 mg/424mg) + Magnesium oxide (50 mg/424mg)TabletOralCho-A Pharm.Co.,Ltd.2017-02-28Not applicableUS flag

Categories

ATC Codes
A02AD02 — MagaldrateA02AF01 — Magaldrate and antiflatulents
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
6V88E24N5T
CAS number
74978-16-8
InChI Key
SPPNVMTVMQOKSC-UHFFFAOYSA-A
InChI
InChI=1S/5Al.10Mg.2H2O4S.32H2O/c;;;;;;;;;;;;;;;2*1-5(2,3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h;;;;;;;;;;;;;;;2*(H2,1,2,3,4);32*1H2/q5*+3;10*+2;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-35
IUPAC Name
pentaaluminium(3+) decamagnesium(2+) hydrate hentriacontahydroxide disulfate
SMILES
O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O

References

Synthesis Reference

U.S. Patent 2,923,660.

General References
  1. Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. [PubMed:8462913]
  2. Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. [PubMed:1790087]
KEGG Drug
D04832
PubChem Compound
3086011
PubChem Substance
310264905
RxNav
29151
ChEMBL
CHEMBL3833350
Drugs.com
Drugs.com Drug Page
Wikipedia
Magaldrate
MSDS
Download (94.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionOral540 mg/5ml
Tablet, chewableOral480 mg
Tablet, chewableOral1080 mg
Suspension200 ml
SuspensionOral800 MG/10ML
SuspensionOral5 g
Tablet800 MG
TabletOral800 MG
GelOral80 MG/ML
Tablet400 MG
Gel80 mg/ml
SuspensionOral800 mg
GelOral1 g
GelOral1600 mg
Tablet, chewableOral800 MG
SuspensionOral
SuspensionOral
TabletOral
Suspension540 mg/5ml
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 22, 2014 13:08 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates